{"id":1045,"date":"2026-07-03T09:03:20","date_gmt":"2026-07-03T09:03:20","guid":{"rendered":"https:\/\/isbm-blow-molding.com\/?p=1045"},"modified":"2026-07-03T09:06:00","modified_gmt":"2026-07-03T09:06:00","slug":"injection-blow-molding-for-pharmaceutical-bottles","status":"publish","type":"post","link":"https:\/\/isbm-blow-molding.com\/bg\/injection-blow-molding-for-pharmaceutical-bottles\/","title":{"rendered":"\u0428\u043f\u0440\u0438\u0446\u0432\u0430\u043d\u0435 \u0447\u0440\u0435\u0437 \u0440\u0430\u0437\u0434\u0443\u0432\u0430\u043d\u0435 \u0437\u0430 \u0444\u0430\u0440\u043c\u0430\u0446\u0435\u0432\u0442\u0438\u0447\u043d\u0438 \u0431\u0443\u0442\u0438\u043b\u043a\u0438"},"content":{"rendered":"<header style=\"position: relative; min-height: min(580px,86vh); display: flex; align-items: center; padding: clamp(40px,6vw,80px) clamp(18px,5vw,56px); box-sizing: border-box; width: 100%; background: #021a0c; background-image: linear-gradient(150deg,rgba(2,12,6,0.97) 0%,rgba(4,30,14,0.75) 55%,rgba(6,95,70,0.30) 100%),url('https:\/\/isbm-blow-molding.com\/wp-content\/uploads\/2026\/07\/Injection-Blow-Molding-Machine-ZQ135.webp'); background-size: cover; background-position: center;\">\n<div style=\"max-width: 680px;\">\n<p><span style=\"display: inline-block; font-size: 10px; font-weight: bold; letter-spacing: 2.5px; text-transform: uppercase; color: #6ee7b7; border: 1px solid rgba(110,231,183,0.32); padding: 4px 12px; border-radius: 3px; margin-bottom: 18px;\">Pharmaceutical IBM \u00b7 Korean KFDA GMP \u00b7 Korea Ever-Power<\/span><\/p>\n<h1 style=\"font-size: clamp(24px,4.2vw,40px); font-weight: 900; color: #fff; line-height: 1.18; margin: 0 0 20px; letter-spacing: -0.5px;\">\u0428\u043f\u0440\u0438\u0446\u0432\u0430\u043d\u0435 \u0447\u0440\u0435\u0437 \u0440\u0430\u0437\u0434\u0443\u0432\u0430\u043d\u0435 \u0437\u0430<br \/>\n\u0424\u0430\u0440\u043c\u0430\u0446\u0435\u0432\u0442\u0438\u0447\u043d\u0438 \u0431\u0443\u0442\u0438\u043b\u043a\u0438<\/h1>\n<p style=\"font-size: clamp(14px,1.9vw,17px); color: #a7f3d0; line-height: 1.7; margin: 0 0 28px; max-width: 560px;\">Injection blow molding is the process standard for Korean pharmaceutical primary packaging in HDPE and PP. It is the only blow molding process that consistently meets Korean KFDA GMP dimensional requirements for CRC containers without secondary neck processing, eliminates particulate contamination risk from flash trimming, and achieves the cavity counts required for Korean pharmaceutical production economics at 10\u2013100 ml formats. This guide covers container formats, Korean KFDA qualification, neck precision, cleanroom considerations and machine selection for Korean pharmaceutical IBM production.<\/p>\n<div style=\"display: flex; flex-wrap: wrap; gap: 8px;\"><span style=\"background: rgba(255,255,255,0.08); border: 1px solid rgba(255,255,255,0.18); color: #a7f3d0; font-size: 11.5px; font-weight: 600; padding: 5px 14px; border-radius: 20px;\">Korean KFDA GMP Qualification<\/span><br \/>\n<span style=\"background: rgba(255,255,255,0.08); border: 1px solid rgba(255,255,255,0.18); color: #a7f3d0; font-size: 11.5px; font-weight: 600; padding: 5px 14px; border-radius: 20px;\">CRC and Neck Precision<\/span><br \/>\n<span style=\"background: rgba(255,255,255,0.08); border: 1px solid rgba(255,255,255,0.18); color: #a7f3d0; font-size: 11.5px; font-weight: 600; padding: 5px 14px; border-radius: 20px;\">Zero Particulate IBM Production<\/span><\/div>\n<p style=\"font-size: 11px; color: #34d399; margin: 22px 0 0;\">\u0418\u043d\u0436\u0435\u043d\u0435\u0440\u043d\u043e \u0431\u044e\u0440\u043e \u201eEver-Power\u201c \u0432 \u041a\u043e\u0440\u0435\u044f \u00b7 \u0410\u043d\u0441\u0430\u043d-\u0441\u0438 \u00b7 \u044e\u043b\u0438 2026 \u0433.<\/p>\n<\/div>\n<\/header>\n<p>&nbsp;<\/p>\n<div style=\"padding: 0px 1%;\"><!-- KPI BAR --><\/p>\n<div style=\"background: #ecfdf5; border: 1px solid #a7f3d0; border-radius: 8px; padding: 20px 24px; margin: 44px 0 0;\">\n<p style=\"font-size: 10.5px; font-weight: 800; letter-spacing: 2px; text-transform: uppercase; color: #065f46; margin: 0 0 14px;\">Pharmaceutical IBM \u2014 Korean Production Reference<\/p>\n<div style=\"display: grid; grid-template-columns: repeat(auto-fit,minmax(min(100%,150px),1fr)); gap: 12px;\">\n<div style=\"background: #fff; border-radius: 6px; padding: 14px; border-top: 3px solid #065f46; text-align: center;\">\n<p style=\"font-size: 20px; font-weight: 900; color: #065f46; margin: 0 0 4px;\">\u00b10,05 \u043c\u043c<\/p>\n<p style=\"font-size: 12px; color: #374151; margin: 0; line-height: 1.4;\">IBM neck OD tolerance \u2014 Korean KFDA CRC qualification standard \u00b10.06 mm<\/p>\n<\/div>\n<div style=\"background: #fff; border-radius: 6px; padding: 14px; border-top: 3px solid #047857; text-align: center;\">\n<p style=\"font-size: 20px; font-weight: 900; color: #065f46; margin: 0 0 4px;\">\u041d\u0443\u043b\u0435\u0432\u0430 \u0441\u0432\u0435\u0442\u043a\u0430\u0432\u0438\u0446\u0430<\/p>\n<p style=\"font-size: 12px; color: #374151; margin: 0; line-height: 1.4;\">No trim station \u2014 no particulate risk in Korean pharmaceutical cleanroom<\/p>\n<\/div>\n<div style=\"background: #fff; border-radius: 6px; padding: 14px; border-top: 3px solid #059669; text-align: center;\">\n<p style=\"font-size: 20px; font-weight: 900; color: #065f46; margin: 0 0 4px;\">\u0414\u043e 30<\/p>\n<p style=\"font-size: 12px; color: #374151; margin: 0; line-height: 1.4;\">Max cavities at 10 ml \u2014 Korean pharmaceutical mega-scale IBM (ZQ135)<\/p>\n<\/div>\n<div style=\"background: #fff; border-radius: 6px; padding: 14px; border-top: 3px solid #10b981; text-align: center;\">\n<p style=\"font-size: 20px; font-weight: 900; color: #065f46; margin: 0 0 4px;\">KFDA \u00b7 ICH<\/p>\n<p style=\"font-size: 12px; color: #374151; margin: 0; line-height: 1.4;\">Korean pharmaceutical IBM container qualification framework alignment<\/p>\n<\/div>\n<\/div>\n<\/div>\n<p><!-- TOC --><\/p>\n<nav style=\"margin: 32px 0 0; background: #f9fafb; border: 1px solid #e5e7eb; border-radius: 8px; padding: 20px 22px;\">\n<p style=\"font-size: 10.5px; font-weight: bold; text-transform: uppercase; letter-spacing: 1.5px; color: #374151; margin: 0 0 12px;\">\u0421\u044a\u0434\u044a\u0440\u0436\u0430\u043d\u0438\u0435<\/p>\n<div style=\"display: grid; grid-template-columns: repeat(auto-fit,minmax(min(100%,260px),1fr)); gap: 4px 20px;\"><a style=\"color: #065f46; text-decoration: none; font-size: 14px; padding: 3px 0; display: block;\" href=\"#s1\">1. Why IBM Is the Korean Pharmaceutical Process Standard<\/a><br \/>\n<a style=\"color: #065f46; text-decoration: none; font-size: 14px; padding: 3px 0; display: block;\" href=\"#s2\">2. Korean KFDA Pharmaceutical Container Requirements<\/a><br \/>\n<a style=\"color: #065f46; text-decoration: none; font-size: 14px; padding: 3px 0; display: block;\" href=\"#s3\">3. HDPE Pharmaceutical IBM Containers<\/a><br \/>\n<a style=\"color: #065f46; text-decoration: none; font-size: 14px; padding: 3px 0; display: block;\" href=\"#s4\">4. PP Pharmaceutical IBM Containers<\/a><br \/>\n<a style=\"color: #065f46; text-decoration: none; font-size: 14px; padding: 3px 0; display: block;\" href=\"#s5\">5. IBM Neck Precision for Pharmaceutical Closures<\/a><br \/>\n<a style=\"color: #065f46; text-decoration: none; font-size: 14px; padding: 3px 0; display: block;\" href=\"#s6\">6. IBM in Korean Pharmaceutical Cleanroom Environments<\/a><br \/>\n<a style=\"color: #065f46; text-decoration: none; font-size: 14px; padding: 3px 0; display: block;\" href=\"#s7\">7. GMP Qualification Documentation for IBM Containers<\/a><br \/>\n<a style=\"color: #065f46; text-decoration: none; font-size: 14px; padding: 3px 0; display: block;\" href=\"#s8\">8. IBM Machine Selection for Korean Pharma Production<\/a><br \/>\n<a style=\"color: #065f46; text-decoration: none; font-size: 14px; padding: 3px 0; display: block;\" href=\"#faq\">\u0427\u0417\u0412<\/a><\/div>\n<\/nav>\n<p><!-- S1 --><\/p>\n<section id=\"s1\" style=\"margin: 56px 0 0; padding: 36px 0 0; border-top: 2px solid #065f46;\">\n<h2 style=\"font-size: clamp(18px,2.6vw,24px); font-weight: 800; color: #065f46; margin: 0 0 18px;\">1. Why IBM Is the Korean Pharmaceutical Process Standard<\/h2>\n<figure style=\"margin: 0 0 22px;\"><img decoding=\"async\" style=\"width: 100%; height: auto; border-radius: 8px; display: block;\" title=\"Korean Pharmaceutical IBM Containers \u2014 Korea Ever-Power\" src=\"https:\/\/isbm-blow-molding.com\/wp-content\/uploads\/2026\/07\/Pharmaceutical-Bottles.webp\" alt=\"Korean pharmaceutical HDPE PP injection blow molded containers \u2014 10ml ophthalmic eye drop bottle 30ml oral liquid vial 100ml CRC child-resistant closure medicine bottle produced by IBM injection blow molding on Korea Ever-Power ZQ80 ZQ110 ZQ135 pharmaceutical IBM machine Korean KFDA GMP primary packaging\" \/><figcaption style=\"font-size: 12px; color: #6b7280; margin-top: 8px; text-align: center;\">Korean pharmaceutical primary containers produced by injection blow molding \u2014 10 ml HDPE ophthalmic (eye drop) bottles, 30 ml oral liquid vials and 100 ml CRC medicine bottles. All three formats require the injection-moulded neck precision that IBM provides as a native process characteristic and that no other blow molding process achieves consistently at production speed without secondary processing.<\/figcaption><\/figure>\n<p style=\"font-size: 16px; margin-bottom: 14px;\">Injection blow molding has established itself as the process standard for Korean pharmaceutical primary packaging in HDPE and PP through the convergence of three process advantages that are uniquely relevant to Korean pharmaceutical production requirements. First, injection-moulded neck precision: IBM produces the bottle neck by injection moulding \u2014 the same precision manufacturing process that produces pharmaceutical closure components \u2014 achieving \u00b10.05 mm neck OD tolerance consistently across all cavities and all production cycles. This precision is the enabling capability for Korean pharmaceutical CRC containers, dropper-cap bottles and pump-dispenser primary containers, all of which require closure engagement at dimensional tolerances that extrusion blow molding cannot achieve without secondary neck processing. Second, zero flash and zero particulate generation: IBM produces no flash at any stage of the process, which means no trim station, no mechanical trimming operation, and no plastic particles generated in the production environment. For Korean pharmaceutical cleanroom production where particulate control is a GMP requirement, IBM&#8217;s inherent particle-free process is a direct regulatory compliance advantage over EBM. Third, multi-cavity efficiency: IBM&#8217;s <a style=\"color: #065f46; font-weight: 600; text-decoration: none;\" href=\"https:\/\/isbm-blow-molding.com\/bg\/product-category\/injection-blow-molding-machine\/\">\u043c\u0430\u0448\u0438\u043d\u0430 \u0437\u0430 \u0448\u043f\u0440\u0438\u0446\u0432\u0430\u043d\u0435 \u0441 \u0440\u0430\u0437\u0434\u0443\u0432\u043d\u0430 \u0444\u043e\u0440\u043c\u0430<\/a> platforms achieve up to 30 cavities at 10 ml \u2014 cavity counts that allow Korean pharmaceutical production economics at single-machine scale that EBM cannot approach at small formats.<\/p>\n<p style=\"font-size: 16px; margin-bottom: 0;\">Korean pharmaceutical container production is further driven by specific Korean regulatory requirements. Korean KFDA (Ministry of Food and Drug Safety) pharmaceutical container regulations require container qualification documentation that includes dimensional compliance, chemical compatibility, extractables and leachables data, and closure function testing \u2014 all of which IBM containers pass through established qualification protocols. Korean pharmaceutical brands, Korean contract manufacturers and Korean pharmaceutical exporters all specify IBM containers for their pharmaceutical primary packaging at small formats as a result of this regulatory and quality alignment.<\/p>\n<\/section>\n<p><!-- S2 --><\/p>\n<section id=\"s2\" style=\"margin: 56px 0 0; padding: 36px 0 0; border-top: 2px solid #e5e7eb;\">\n<h2 style=\"font-size: clamp(18px,2.6vw,24px); font-weight: 800; color: #065f46; margin: 0 0 18px;\">2. Korean KFDA Pharmaceutical Container Requirements<\/h2>\n<p style=\"font-size: 16px; margin-bottom: 14px;\">Korean pharmaceutical primary container requirements are established by Korean KFDA (\uc2dd\ud488\uc758\uc57d\ud488\uc548\uc804\ucc98) under the Korean Pharmaceutical Affairs Act and the Korean Pharmacopoeia (KP). Korean pharmaceutical container requirements align substantially with ICH Q6A specifications and USP\/EP plastic container standards, with Korean-specific additions for certain container format types. Korean pharmaceutical IBM container producers must understand which KFDA requirements apply to their specific container formats before beginning the Korean pharmaceutical qualification process.<\/p>\n<h3 style=\"font-size: clamp(16px,2vw,20px); color: #065f46; font-weight: bold; margin: 0 0 10px;\">Korean KFDA Plastic Container Standards<\/h3>\n<p style=\"font-size: 16px; margin-bottom: 14px;\">Korean Pharmacopoeia (KP) General Monograph for Plastic Containers for Pharmaceutical Use specifies test requirements for HDPE and PP pharmaceutical containers including: extractables below KP limits in water, 4% acetic acid, ethanol 20%, heptane and methanol extraction media; heavy metals below 1 ppm; phenol below 5 ppm; UV absorbance within limits. IBM containers must pass these tests at the specified wall thickness using the production HDPE or PP resin grade \u2014 not a laboratory test specimen. Korean pharmaceutical IBM producers should conduct extractables testing on actual production containers from their IBM machine at their production conditions, using resin from the same commercial lot that will supply production, to ensure that test results represent the commercial product that Korean pharmaceutical brands will validate.<\/p>\n<p style=\"font-size: 16px; margin-bottom: 14px;\">Korean KFDA additionally requires specific dimensional documentation for pharmaceutical primary containers used with registered Korean pharmaceutical products. The Korean pharmaceutical dossier (Korean NDA equivalent) includes container specifications covering: nominal volume with fill-level mark position, neck OD and bore diameter with tolerances, closure engagement torque specification, container material identification (resin type, grade, Korean KFDA positive list status), and colour (transparent, natural HDPE, pigmented HDPE if applicable). Any change to the container specification \u2014 including resin lot change, production machine change, or cavity count change \u2014 requires a Korean KFDA container change notification and may require re-qualification testing depending on the nature of the change.<\/p>\n<h3 style=\"font-size: clamp(16px,2vw,20px); color: #065f46; font-weight: bold; margin: 28px 0 10px;\">Key Container Format Requirements<\/h3>\n<div style=\"overflow-x: auto; margin: 12px 0 0;\">\n<table style=\"width: 100%; border-collapse: collapse; font-size: 13.5px; min-width: 480px;\">\n<thead>\n<tr style=\"background: #065f46;\">\n<th style=\"color: #fff; padding: 10px 12px; text-align: left; font-weight: bold;\">Container Format<\/th>\n<th style=\"color: #fff; padding: 10px 12px; text-align: left; font-weight: bold;\">Korean KFDA Key Requirement<\/th>\n<th style=\"color: #fff; padding: 10px 12px; text-align: left; font-weight: bold;\">IBM Compliance Status<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 9px 12px; border-bottom: 1px solid #a7f3d0; font-weight: 600;\">Ophthalmic (eye drop)<\/td>\n<td style=\"padding: 9px 12px; border-bottom: 1px solid #a7f3d0;\">Sterile filling compatibility, dropper tip fit \u00b10.05 mm, particulate free (KFDA injectables standard)<\/td>\n<td style=\"padding: 9px 12px; border-bottom: 1px solid #a7f3d0; color: #166534; font-weight: bold;\">Native \u2014 injection neck, zero flash \u2713<\/td>\n<\/tr>\n<tr style=\"background: #ecfdf5;\">\n<td style=\"padding: 9px 12px; border-bottom: 1px solid #a7f3d0; font-weight: 600;\">CRC Medicine Bottle<\/td>\n<td style=\"padding: 9px 12px; border-bottom: 1px solid #a7f3d0;\">CRC cap engagement per KS M ISO 8317, neck OD \u00b10.06 mm, thread OD \u00b10.05 mm<\/td>\n<td style=\"padding: 9px 12px; border-bottom: 1px solid #a7f3d0; color: #166534; font-weight: bold;\">Native \u2014 injection neck \u00b10.05 mm \u2713<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 9px 12px; border-bottom: 1px solid #a7f3d0; font-weight: 600;\">Oral Liquid Vial<\/td>\n<td style=\"padding: 9px 12px; border-bottom: 1px solid #a7f3d0;\">Induction seal compatibility, neck flatness \u00b10.1 mm, chemical compatibility 24-month<\/td>\n<td style=\"padding: 9px 12px; border-bottom: 1px solid #a7f3d0; color: #166534; font-weight: bold;\">Native \u2014 flat neck sealing surface \u2713<\/td>\n<\/tr>\n<tr style=\"background: #ecfdf5;\">\n<td style=\"padding: 9px 12px; border-bottom: 1px solid #a7f3d0; font-weight: 600;\">Pump Dispenser Primary<\/td>\n<td style=\"padding: 9px 12px; border-bottom: 1px solid #a7f3d0;\">Pump collar engagement, neck bore \u00b10.08 mm, chemical compatibility<\/td>\n<td style=\"padding: 9px 12px; border-bottom: 1px solid #a7f3d0; color: #166534; font-weight: bold;\">Native \u2014 injection neck bore precision \u2713<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 9px 12px; font-weight: 600;\">Autoclave PP Container<\/td>\n<td style=\"padding: 9px 12px;\">121\u00b0C steam resistance, dimensional retention post-autoclave, KP plastic test<\/td>\n<td style=\"padding: 9px 12px; color: #166534; font-weight: bold;\">PP IBM \u2014 heat-resistant grade required \u2713<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/section>\n<p><!-- S3 --><\/p>\n<section id=\"s3\" style=\"margin: 56px 0 0; padding: 36px 0 0; border-top: 2px solid #e5e7eb;\">\n<h2 style=\"font-size: clamp(18px,2.6vw,24px); font-weight: 800; color: #065f46; margin: 0 0 18px;\">3. HDPE Pharmaceutical IBM Containers: Formats and Specifications<\/h2>\n<figure style=\"margin: 0 0 22px;\"><img decoding=\"async\" style=\"width: 100%; height: auto; border-radius: 8px; display: block;\" title=\"Pharmaceutical IBM Mould \u2014 Korea Ever-Power 20-Cavity\" src=\"https:\/\/isbm-blow-molding.com\/wp-content\/uploads\/2026\/07\/IBM-mold-3.webp\" alt=\"Pharmaceutical IBM mould set \u2014 20-cavity HDPE ophthalmic pharmaceutical injection blow molding mould with S136 stainless steel cavity bodies and core rods, hot runner manifold with 20-drop balanced gate system, cavity-by-cavity weight qualification report \u2014 Korea Ever-Power ZQ80 ZQ110 pharmaceutical IBM mould Korean KFDA GMP qualification documentation\" \/><figcaption style=\"font-size: 12px; color: #6b7280; margin-top: 8px; text-align: center;\">Korea Ever-Power pharmaceutical IBM mould set \u2014 S136 stainless steel cavity bodies and core rods for Korean pharmaceutical HDPE container production, with balanced 20-drop hot runner manifold. The cavity-by-cavity weight and dimensional qualification report produced from 500 consecutive production cycles on this mould before shipment forms part of the Korean KFDA pharmaceutical container qualification documentation package.<\/figcaption><\/figure>\n<p style=\"font-size: 16px; margin-bottom: 14px;\">HDPE is the dominant material for Korean pharmaceutical IBM containers \u2014 accounting for the majority of Korean pharmaceutical primary container production volume in HDPE IBM. The complete pharmaceutical HDPE IBM guide is covered in the <a style=\"color: #065f46; font-weight: 600; text-decoration: none;\" href=\"https:\/\/isbm-blow-molding.com\/bg\/hdpe-injection-blow-molding\/\">\u0420\u044a\u043a\u043e\u0432\u043e\u0434\u0441\u0442\u0432\u043e \u0437\u0430 \u043e\u0431\u0440\u0430\u0431\u043e\u0442\u043a\u0430 \u043d\u0430 HDPE IBM<\/a>; this section focuses on the pharmaceutical-specific requirements for each HDPE IBM container format.<\/p>\n<h3 style=\"font-size: clamp(16px,2vw,20px); color: #065f46; font-weight: bold; margin: 0 0 10px;\">10 ml Ophthalmic Bottles \u2014 the Korean Pharmaceutical IBM Volume Leader<\/h3>\n<p style=\"font-size: 16px; margin-bottom: 14px;\">Korean 10 ml HDPE ophthalmic containers are the highest-volume pharmaceutical IBM format in Korea \u2014 the combination of Korean ophthalmic prescription volume (Korea has one of East Asia&#8217;s highest rates of ophthalmic prescription per capita, driven by Korean contact lens use and Korean digital eye fatigue), Korean OTC artificial tear market and Korean pharmaceutical export requirements produces annual Korean ophthalmic container volume above 500 million units. IBM is the process of record for Korean ophthalmic containers because the dropper tip&#8217;s aperture, the dropper cap thread engagement and the container body&#8217;s sufficient transparency for fill-level inspection all require IBM&#8217;s precision that EBM cannot match. HDPE grade for Korean ophthalmic IBM: MI 0.3\u20130.5, density 0.950\u20130.960, pharmaceutical-grade additive package per KFDA positive list. Wall thickness: body 0.30\u20130.40 mm (sufficient transparency for fill-level check), neck 0.9\u20131.2 mm (closure retention). Production: Korea Ever-Power ZQ80 (20 cavities \u2192 ~15,800\/hour) and ZQ110 (24 cavities \u2192 ~19,000\/hour) are the principal Korean ophthalmic IBM platforms.<\/p>\n<h3 style=\"font-size: clamp(16px,2vw,20px); color: #065f46; font-weight: bold; margin: 28px 0 10px;\">30 ml Oral Liquid Vials<\/h3>\n<p style=\"font-size: 16px; margin-bottom: 14px;\">Korean 30 ml HDPE oral liquid vials serve unit-dose liquid medications \u2014 Korean syrups for paediatric use, Korean liquid vitamin preparations and Korean oral rehydration solutions. These formats require IBM for two specific reasons: the induction seal compatibility of the neck&#8217;s flat sealing surface (IBM&#8217;s injection mould produces the flat sealing land with Ra \u2264 0.05 \u03bcm required for consistent induction seal bonding across all 18\u201320 cavities) and the fill-level transparency of the HDPE body. At 30 ml, the IBM machine produces 18 cavities on the ZQ80 (approximately 16,200 vials per hour) or up to 22 cavities on the ZQ110 (approximately 19,800 vials per hour) \u2014 output rates that match Korean oral liquid pharmaceutical production line speeds without requiring multiple IBM machines for a single product line.<\/p>\n<h3 style=\"font-size: clamp(16px,2vw,20px); color: #065f46; font-weight: bold; margin: 28px 0 10px;\">100 \u043c\u043b \u0431\u0443\u0442\u0438\u043b\u043a\u0438 \u0437\u0430 \u043b\u0435\u043a\u0430\u0440\u0441\u0442\u0432\u0430 CRC<\/h3>\n<p style=\"font-size: 16px; margin-bottom: 0;\">Korean CRC medicine bottles in HDPE at 100 ml are the most demanding pharmaceutical IBM format from a dimensional tolerance perspective. Korean KS M ISO 8317 child-resistant closure testing requires that less than 20% of adult test subjects fail to open the container within 5 minutes (CRC must be child-resistant but adult-accessible). This functional balance is achieved by the CRC cap&#8217;s mechanical engagement with the bottle neck&#8217;s engagement bead \u2014 an engagement that depends on the bead OD being within \u00b10.06 mm of the CRC cap&#8217;s designed engagement diameter. IBM&#8217;s \u00b10.05 mm neck OD tolerance is within this requirement; EBM&#8217;s \u00b10.15\u20130.25 mm tolerance is not. HDPE grade for CRC IBM: MI 0.5\u20130.8 for a stiffer bead that resists deformation under CRC cap push-down force; density 0.955\u20130.965 for maximum bead stiffness at the engagement contact zone.<\/p>\n<\/section>\n<p><!-- S4 --><\/p>\n<section id=\"s4\" style=\"margin: 56px 0 0; padding: 36px 0 0; border-top: 2px solid #e5e7eb;\">\n<h2 style=\"font-size: clamp(18px,2.6vw,24px); font-weight: 800; color: #065f46; margin: 0 0 18px;\">4. PP Pharmaceutical IBM Containers: When PP Is Required Over HDPE<\/h2>\n<p style=\"font-size: 16px; margin-bottom: 14px;\">Polypropylene (PP) is required over HDPE for Korean pharmaceutical IBM containers in two well-defined application categories: terminal steam sterilisation (autoclave) and high-temperature pharmaceutical processes. PP&#8217;s heat deflection temperature (110\u2013120\u00b0C at 0.45 MPa) allows it to retain dimensional integrity through Korean standard autoclave cycles at 121\u00b0C for 20 minutes, whereas HDPE begins to deform above 80\u201385\u00b0C under steam pressure and closure torque.<\/p>\n<h3 style=\"font-size: clamp(16px,2vw,20px); color: #065f46; font-weight: bold; margin: 0 0 10px;\">Korean Autoclavable PP IBM Containers<\/h3>\n<p style=\"font-size: 16px; margin-bottom: 14px;\">Korean terminally sterilised pharmaceutical products \u2014 including some Korean ophthalmic preparations, Korean irrigating solutions and Korean topical pharmaceutical formulations \u2014 require primary containers that survive the autoclave cycle without dimensional change at the closure engagement zone. PP IBM containers for Korean autoclave use specify: PP copolymer grade (homopolymer PP has better heat resistance but is more brittle; random copolymer PP offers better clarity and impact resistance at a slight reduction in heat resistance \u2014 for Korean pharmaceutical autoclave at 121\u00b0C, either grade is adequate); melt flow rate 5\u201315 g\/10min at 230\u00b0C\/2.16 kg (higher MFR than HDPE IBM grades, matching PP&#8217;s typically higher flowability); barrel temperature 200\u2013240\u00b0C on Korea Ever-Power ZQ series machines (higher than HDPE processing, requiring barrel zone setpoints adjusted from the HDPE baseline); dimensional verification post-autoclave (container neck OD and thread dimensions must be within specification after 3 autoclave cycles at 121\u00b0C\/20 min \u2014 this post-autoclave dimensional verification is a KFDA qualification requirement for terminally sterilised Korean pharmaceutical containers).<\/p>\n<h3 style=\"font-size: clamp(16px,2vw,20px); color: #065f46; font-weight: bold; margin: 28px 0 10px;\">PP vs HDPE IBM Processing Differences on ZQ Series Machines<\/h3>\n<div style=\"overflow-x: auto; margin: 12px 0 0;\">\n<table style=\"width: 100%; border-collapse: collapse; font-size: 13.5px; min-width: 460px;\">\n<thead>\n<tr style=\"background: #065f46;\">\n<th style=\"color: #fff; padding: 10px 12px; text-align: left; font-weight: bold;\">\u041f\u0430\u0440\u0430\u043c\u0435\u0442\u044a\u0440 \u0437\u0430 \u043e\u0431\u0440\u0430\u0431\u043e\u0442\u043a\u0430<\/th>\n<th style=\"color: #fff; padding: 10px 12px; text-align: center; font-weight: bold;\">HDPE (MI 0.3\u20130.8)<\/th>\n<th style=\"color: #fff; padding: 10px 12px; text-align: center; font-weight: bold;\">PP (MFR 5\u201315)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 9px 12px; border-bottom: 1px solid #a7f3d0; font-weight: 600;\">Metering zone temp<\/td>\n<td style=\"padding: 9px 12px; border-bottom: 1px solid #a7f3d0; text-align: center;\">200\u2013215\u00b0C<\/td>\n<td style=\"padding: 9px 12px; border-bottom: 1px solid #a7f3d0; text-align: center; font-weight: bold;\">220\u2013235\u00b0C<\/td>\n<\/tr>\n<tr style=\"background: #ecfdf5;\">\n<td style=\"padding: 9px 12px; border-bottom: 1px solid #a7f3d0; font-weight: 600;\">Injection nozzle temp<\/td>\n<td style=\"padding: 9px 12px; border-bottom: 1px solid #a7f3d0; text-align: center;\">210\u2013220\u00b0C<\/td>\n<td style=\"padding: 9px 12px; border-bottom: 1px solid #a7f3d0; text-align: center; font-weight: bold;\">230\u2013245\u00b0C<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 9px 12px; border-bottom: 1px solid #a7f3d0; font-weight: 600;\">\u041d\u0430\u043b\u044f\u0433\u0430\u043d\u0435 \u043d\u0430 \u0438\u043d\u0436\u0435\u043a\u0442\u0438\u0440\u0430\u043d\u0435<\/td>\n<td style=\"padding: 9px 12px; border-bottom: 1px solid #a7f3d0; text-align: center;\">80\u2013140 MPa<\/td>\n<td style=\"padding: 9px 12px; border-bottom: 1px solid #a7f3d0; text-align: center; font-weight: bold;\">60\u2013110 MPa (lower viscosity)<\/td>\n<\/tr>\n<tr style=\"background: #ecfdf5;\">\n<td style=\"padding: 9px 12px; border-bottom: 1px solid #a7f3d0; font-weight: 600;\">\u0412\u0440\u0435\u043c\u0435 \u043d\u0430 \u0437\u0430\u0434\u044a\u0440\u0436\u0430\u043d\u0435 \u043d\u0430 \u0434\u0443\u0445\u0430\u043d\u0435\u0442\u043e<\/td>\n<td style=\"padding: 9px 12px; border-bottom: 1px solid #a7f3d0; text-align: center;\">0.8\u20131.5 s<\/td>\n<td style=\"padding: 9px 12px; border-bottom: 1px solid #a7f3d0; text-align: center; font-weight: bold;\">1.0\u20132.0 s (slower crystallisation)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 9px 12px; border-bottom: 1px solid #a7f3d0; font-weight: 600;\">\u0422\u0435\u043c\u043f\u0435\u0440\u0430\u0442\u0443\u0440\u0430 \u043d\u0430 \u043f\u043b\u0435\u0441\u0435\u043d\u0442\u0430<\/td>\n<td style=\"padding: 9px 12px; border-bottom: 1px solid #a7f3d0; text-align: center;\">15\u201325\u00b0C<\/td>\n<td style=\"padding: 9px 12px; border-bottom: 1px solid #a7f3d0; text-align: center; font-weight: bold;\">20\u201340\u00b0C (PP needs slower cooling to prevent stress whitening)<\/td>\n<\/tr>\n<tr style=\"background: #ecfdf5;\">\n<td style=\"padding: 9px 12px; font-weight: 600;\">Post-autoclave dimensional check<\/td>\n<td style=\"padding: 9px 12px; text-align: center;\">\u041d\u0435 \u0435 \u0437\u0430\u0434\u044a\u043b\u0436\u0438\u0442\u0435\u043b\u043d\u043e<\/td>\n<td style=\"padding: 9px 12px; text-align: center; font-weight: bold; color: #065f46;\">Required \u2014 Korean KFDA qualification<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/section>\n<p><!-- S5 --><\/p>\n<section id=\"s5\" style=\"margin: 56px 0 0; padding: 36px 0 0; border-top: 2px solid #e5e7eb;\">\n<h2 style=\"font-size: clamp(18px,2.6vw,24px); font-weight: 800; color: #065f46; margin: 0 0 18px;\">5. IBM Neck Precision for Pharmaceutical Closures<\/h2>\n<figure style=\"margin: 0 0 22px;\"><img decoding=\"async\" style=\"width: 100%; height: auto; border-radius: 8px; display: block;\" title=\"IBM Neck Precision Mechanism \u2014 Core Rod Through Neck Zone\" src=\"https:\/\/isbm-blow-molding.com\/wp-content\/uploads\/2026\/07\/IBM-Internal-structure.webp\" alt=\"IBM machine internal structure showing core rod mechanism producing pharmaceutical neck precision \u2014 core rod passes through neck zone during both injection and blow, defining neck OD at \u00b10.05mm, thread profile, sealing surface flatness and bore diameter for Korean pharmaceutical CRC dropper induction seal and pump neck closure engagement\" \/><figcaption style=\"font-size: 12px; color: #6b7280; margin-top: 8px; text-align: center;\">IBM neck precision mechanism \u2014 the core rod passes through the neck zone during both injection (defining the bore diameter and thread root geometry) and blow phases (preventing any blow pressure from deforming the injection-moulded neck geometry). This dual-phase core rod engagement is what produces IBM&#8217;s \u00b10.05 mm neck OD \u2014 impossible to achieve in extrusion blow molding where the neck is formed by a parting line rather than a precision tool.<\/figcaption><\/figure>\n<p style=\"font-size: 16px; margin-bottom: 14px;\">Pharmaceutical closure function is the most demanding test of IBM neck precision. Every Korean pharmaceutical closure system \u2014 CRC caps, dropper tips, induction seals, pump collars and spray actuators \u2014 specifies dimensional requirements for the container neck that the closure interacts with. IBM&#8217;s \u00b10.05 mm neck OD tolerance is the process characteristic that allows Korean pharmaceutical IBM containers to pass closure function tests across all cavities simultaneously, at production sampling frequencies, without statistical outliers at the tolerance edges.<\/p>\n<h3 style=\"font-size: clamp(16px,2vw,20px); color: #065f46; font-weight: bold; margin: 0 0 10px;\">CRC Neck Requirements for Korean Pharmaceutical IBM<\/h3>\n<p style=\"font-size: 16px; margin-bottom: 14px;\">Korean CRC containers must pass Korean KS M ISO 8317 child-resistant effectiveness testing \u2014 a formal protocol where 200 adult test subjects and 200 child test subjects each attempt to open the container under specified conditions. The mechanical function of the push-and-turn CRC cap depends on its ratchet teeth engaging the neck bead at a specific interference fit: too wide (neck OD too high) and the cap cannot be rotated \u2014 adult accessibility fails; too narrow (neck OD too low) and the cap can be rotated without depression \u2014 child resistance fails. The tolerance window for the neck engagement bead OD in Korean pharmaceutical CRC containers is typically \u00b10.06 mm from the CRC cap manufacturer&#8217;s specified nominal. IBM&#8217;s \u00b10.05 mm neck OD is within this window; EBM&#8217;s \u00b10.15\u20130.25 mm exceeds it. At 24-cavity production on a ZQ110, all 24 cavities must individually produce neck OD within the \u00b10.06 mm window on every cycle \u2014 a requirement that IBM meets through its injection-moulded neck insert precision, which holds the neck OD regardless of blow air pressure, cycle time variation or mould cooling variation.<\/p>\n<h3 style=\"font-size: clamp(16px,2vw,20px); color: #065f46; font-weight: bold; margin: 28px 0 10px;\">Dropper Tip and Induction Seal Neck Requirements<\/h3>\n<p style=\"font-size: 16px; margin-bottom: 0;\">Korean ophthalmic dropper caps use a snap-fit aperture control insert that seats inside the bottle neck bore, with the insert&#8217;s outer diameter engaging the bore inner surface at a specific interference. IBM&#8217;s injection mould core rod defines the bore inner diameter with \u00b10.04 mm tolerance \u2014 directly translating to \u00b10.04 mm aperture control insert fit variation. For Korean induction seal containers (30 ml oral liquid, 100 ml multi-dose liquid), the neck&#8217;s flat sealing land must be flat within 0.1 mm TIR (total indicator runout) for the induction foil to bond uniformly without gaps. IBM&#8217;s injection mould produces the sealing land surface with the same precision as a machined engineering component \u2014 flatness \u00b10.05 mm TIR across all cavities \u2014 because the sealing land is formed by the injection mould face rather than by a parting line or pinch-off as in EBM.<\/p>\n<\/section>\n<p><!-- S6 --><\/p>\n<section id=\"s6\" style=\"margin: 56px 0 0; padding: 36px 0 0; border-top: 2px solid #e5e7eb;\">\n<h2 style=\"font-size: clamp(18px,2.6vw,24px); font-weight: 800; color: #065f46; margin: 0 0 18px;\">6. IBM in Korean Pharmaceutical Cleanroom Environments<\/h2>\n<p style=\"font-size: 16px; margin-bottom: 14px;\">Korean pharmaceutical primary container production is increasingly conducted in ISO Class 8 or better cleanroom environments \u2014 particularly for ophthalmic containers, injectable primary packaging, and multi-dose liquid containers where particulate contamination in the container before filling is a KFDA pharmaceutical quality risk. IBM&#8217;s zero-flash production is a direct cleanroom compliance advantage because the particle generation mechanisms inherent to EBM \u2014 the flash trim station&#8217;s mechanical cutting, the flash removal conveyor, and the regrind system \u2014 are entirely absent from an IBM production cell.<\/p>\n<p style=\"font-size: 16px; margin-bottom: 14px;\">Korean pharmaceutical cleanroom IBM cell design requirements for ISO Class 8 (equivalent to Korean GMP Grade D) container production: the IBM machine&#8217;s mould area \u2014 where containers are formed and where the output conveyor receives the containers \u2014 should be enclosed under HEPA-filtered positive-pressure supply air at a minimum of 0.45 m\/s face velocity and 20 air changes per hour. Korea Ever-Power&#8217;s ZQ series machines accommodate HEPA enclosure installation by the Korean customer&#8217;s HVAC engineering team, with connection points for supply air ductwork identified in the ZQ machine layout drawings provided at order. The IBM machine&#8217;s hydraulic system should be filled with pharmaceutical-compatible food-grade hydraulic oil (specified as an option on ZQ80, ZQ110 and ZQ135) to prevent non-compliant mineral oil contamination if any hydraulic system seepage occurs in the cleanroom environment.<\/p>\n<p style=\"font-size: 16px; margin-bottom: 0;\">Korea Ever-Power&#8217;s dual hydraulic system (standard on the <a style=\"color: #065f46; font-weight: 600; text-decoration: none;\" href=\"https:\/\/isbm-blow-molding.com\/bg\/product\/ep-zq80-injection-blow-molding-machine-european-style\/\">ZQ80<\/a> and above) provides a secondary cleanroom benefit: its 20\u201330% energy saving versus single-circuit competitor IBM machines reduces the waste heat load generated per unit of container output in the cleanroom space, which reduces the HVAC cooling demand required to maintain the cleanroom temperature set point (typically 20\u201322\u00b0C for Korean pharmaceutical cleanrooms). For Korean pharmaceutical factories where cleanroom HVAC energy is a significant operating cost, the ZQ80 and above models&#8217; dual hydraulic energy efficiency contributes to reduced HVAC loads per unit of production output \u2014 a compounding benefit on top of the direct machine energy saving.<\/p>\n<\/section>\n<p><!-- S7 --><\/p>\n<section id=\"s7\" style=\"margin: 56px 0 0; padding: 36px 0 0; border-top: 2px solid #e5e7eb;\">\n<h2 style=\"font-size: clamp(18px,2.6vw,24px); font-weight: 800; color: #065f46; margin: 0 0 18px;\">7. GMP Qualification Documentation for Korean Pharmaceutical IBM Containers<\/h2>\n<figure style=\"margin: 0 0 22px;\"><img decoding=\"async\" style=\"width: 100%; height: auto; border-radius: 8px; display: block;\" title=\"Korea Ever-Power Workshop \u2014 Pharmaceutical IBM Manufacturing and GMP Documentation\" src=\"https:\/\/isbm-blow-molding.com\/wp-content\/uploads\/2026\/07\/ever-power-workshop-1.webp\" alt=\"Korea Ever-Power pharmaceutical IBM machine manufacturing workshop \u2014 ZQ series pharmaceutical IBM machine quality control precision assembly and pre-delivery testing with GMP container qualification documentation package preparation for Korean KFDA pharmaceutical supplier qualification\" \/><figcaption style=\"font-size: 12px; color: #6b7280; margin-top: 8px; text-align: center;\">Korea Ever-Power&#8217;s manufacturing facility \u2014 each pharmaceutical IBM machine undergoes pre-delivery testing with the customer&#8217;s mould set installed, producing cavity-by-cavity dimensional data included in the Korean KFDA pharmaceutical container qualification documentation package delivered with the machine and mould. This pre-delivery qualification support reduces the Korean customer&#8217;s on-site qualification timeline by providing verified dimensional data before installation.<\/figcaption><\/figure>\n<p style=\"font-size: 16px; margin-bottom: 14px;\">Korean pharmaceutical IBM container qualification follows a structured documentation pathway that Korean pharmaceutical brands require from their IBM container suppliers. Understanding this pathway allows Korean IBM packaging producers to prepare the correct documentation in advance, reducing the qualification timeline and avoiding KFDA submission delays caused by missing technical data.<\/p>\n<div style=\"display: flex; flex-direction: column; gap: 12px; margin: 16px 0 24px;\">\n<div style=\"background: #ecfdf5; border-left: 4px solid #065f46; border-radius: 0 6px 6px 0; padding: 16px 20px;\">\n<p style=\"font-weight: bold; color: #065f46; margin: 0 0 6px;\">Stage 1 \u2014 Container Technical File<\/p>\n<p style=\"font-size: 15px; color: #374151; margin: 0; line-height: 1.65;\">Material specification sheet (resin manufacturer, grade, MI, density, Korean KFDA positive list reference); container dimensional drawing with all nominal dimensions and tolerances; production machine and mould identification; production site address and Korean KFDA-registered packaging facility status (if applicable). Korea Ever-Power provides this documentation as part of the standard ZQ series delivery package.<\/p>\n<\/div>\n<div style=\"background: #ecfdf5; border-left: 4px solid #047857; border-radius: 0 6px 6px 0; padding: 16px 20px;\">\n<p style=\"font-weight: bold; color: #065f46; margin: 0 0 6px;\">Stage 2 \u2014 Container Qualification Testing<\/p>\n<p style=\"font-size: 15px; color: #374151; margin: 0; line-height: 1.65;\">Korean Pharmacopoeia plastic container test results (extractables from Korean accredited laboratory); dimensional measurement report (cavity-by-cavity, 30 measurements per dimension, 3 production batches); closure engagement test (CRC per KS M ISO 8317, induction seal per ASTM F2096 or equivalent Korean standard, dropper tip insertion torque); chemical compatibility compatibility test (12-week filled stability at 40\u00b0C\/75% RH with the specific pharmaceutical formulation). Korea Ever-Power provides the cavity-by-cavity dimensional report from pre-delivery production trials as part of standard delivery \u2014 reducing the Korean customer&#8217;s testing burden at Stage 2.<\/p>\n<\/div>\n<div style=\"background: #ecfdf5; border-left: 4px solid #059669; border-radius: 0 6px 6px 0; padding: 16px 20px;\">\n<p style=\"font-weight: bold; color: #065f46; margin: 0 0 6px;\">Stage 3 \u2014 Korean KFDA Container Change Notification (if applicable)<\/p>\n<p style=\"font-size: 15px; color: #374151; margin: 0; line-height: 1.65;\">For Korean pharmaceutical products with existing KFDA registration using a different container supplier or container specification: Korean KFDA container change notification procedure under Korean Pharmaceutical Affairs Act Article 32. Minor changes (same material class, same container type, within original dimensional tolerance) may be self-declared by the Korean pharmaceutical manufacturer. Major changes (material change, closure type change, dimensional tolerance change) require Korean KFDA review and approval before commercial production use. Timeline: minor change self-declaration = immediate; major change KFDA review = 3\u20136 months at current Korean KFDA review throughput.<\/p>\n<\/div>\n<\/div>\n<\/section>\n<p><!-- S8 --><\/p>\n<section id=\"s8\" style=\"margin: 56px 0 0; padding: 36px 0 0; border-top: 2px solid #e5e7eb;\">\n<h2 style=\"font-size: clamp(18px,2.6vw,24px); font-weight: 800; color: #065f46; margin: 0 0 18px;\">8. IBM Machine Selection for Korean Pharmaceutical Production<\/h2>\n<p style=\"font-size: 16px; margin-bottom: 20px;\">Korean pharmaceutical IBM machine selection follows the same annual volume framework as other IBM applications, with one additional consideration specific to pharmaceutical production: Korean GMP supplier qualification requires qualification at a specific machine (identified by machine serial number) and cavity count. Changing to a higher-cavity machine after initial qualification requires re-qualification \u2014 a cost and timeline consideration that makes initial machine selection at the correct scale more important for pharmaceutical IBM than for household chemical IBM where format flexibility is higher and re-qualification requirements are less demanding.<\/p>\n<div style=\"overflow-x: auto; margin: 0 0 24px;\">\n<table style=\"width: 100%; border-collapse: collapse; font-size: 13.5px; min-width: 500px;\">\n<thead>\n<tr style=\"background: #065f46;\">\n<th style=\"color: #fff; padding: 10px 12px; text-align: left; font-weight: bold;\">Annual Volume (10 ml pharma)<\/th>\n<th style=\"color: #fff; padding: 10px 12px; text-align: center; font-weight: bold;\">ZQ \u043c\u043e\u0434\u0435\u043b<\/th>\n<th style=\"color: #fff; padding: 10px 12px; text-align: center; font-weight: bold;\">Cavities @10ml<\/th>\n<th style=\"color: #fff; padding: 10px 12px; text-align: left; font-weight: bold;\">Korean Pharma Profile<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 9px 12px; border-bottom: 1px solid #a7f3d0; font-weight: 600;\">Below 15M \/ year<\/td>\n<td style=\"padding: 9px 12px; border-bottom: 1px solid #a7f3d0; text-align: center; font-weight: bold; color: #065f46;\">ZQ40<\/td>\n<td style=\"padding: 9px 12px; border-bottom: 1px solid #a7f3d0; text-align: center;\">9<\/td>\n<td style=\"padding: 9px 12px; border-bottom: 1px solid #a7f3d0;\">Korean pharma startup, Korean clinical trial material supply, Korean rare disease specialty<\/td>\n<\/tr>\n<tr style=\"background: #ecfdf5;\">\n<td style=\"padding: 9px 12px; border-bottom: 1px solid #a7f3d0; font-weight: 600;\">15M\u201330M \/ year<\/td>\n<td style=\"padding: 9px 12px; border-bottom: 1px solid #a7f3d0; text-align: center; font-weight: bold; color: #065f46;\">ZQ60<\/td>\n<td style=\"padding: 9px 12px; border-bottom: 1px solid #a7f3d0; text-align: center;\">14<\/td>\n<td style=\"padding: 9px 12px; border-bottom: 1px solid #a7f3d0;\">Korean mid-scale pharma, Korean regional hospital supply, Korean OTC pharma container<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 9px 12px; border-bottom: 1px solid #a7f3d0; font-weight: 600;\">30M\u201350M \/ year<\/td>\n<td style=\"padding: 9px 12px; border-bottom: 1px solid #a7f3d0; text-align: center; font-weight: bold; color: #065f46;\">ZQ80<\/td>\n<td style=\"padding: 9px 12px; border-bottom: 1px solid #a7f3d0; text-align: center;\">20<\/td>\n<td style=\"padding: 9px 12px; border-bottom: 1px solid #a7f3d0;\">Korean large pharmaceutical, Korean contract pharma packaging, Korean pharma exporter<\/td>\n<\/tr>\n<tr style=\"background: #ecfdf5;\">\n<td style=\"padding: 9px 12px; border-bottom: 1px solid #a7f3d0; font-weight: 600;\">50M\u201365M \/ year<\/td>\n<td style=\"padding: 9px 12px; border-bottom: 1px solid #a7f3d0; text-align: center; font-weight: bold; color: #065f46;\">ZQ110<\/td>\n<td style=\"padding: 9px 12px; border-bottom: 1px solid #a7f3d0; text-align: center;\">24<\/td>\n<td style=\"padding: 9px 12px; border-bottom: 1px solid #a7f3d0;\">Korean large-scale contract pharmaceutical packaging, Korean multi-product pharma<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 9px 12px; font-weight: 600;\">Above 65M \/ year<\/td>\n<td style=\"padding: 9px 12px; text-align: center; font-weight: bold; color: #065f46;\">ZQ135<\/td>\n<td style=\"padding: 9px 12px; text-align: center;\">30<\/td>\n<td style=\"padding: 9px 12px;\">Korean national pharmaceutical manufacturer, Korean hospital supply chain contract packaging<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p style=\"font-size: 16px; margin-bottom: 0;\"><strong>Re-qualification strategy for Korean pharmaceutical IBM scale-up:<\/strong> Korean pharmaceutical IBM producers who anticipate scale-up from ZQ60 to ZQ80 within 3 years should consider qualifying both machines simultaneously at initial installation \u2014 qualifying the ZQ60 as the primary production machine and the ZQ80 as the approved secondary machine in the same Korean KFDA container change notification. This pre-emptive dual-machine qualification adds modest documentation cost at initial qualification but avoids the 3\u20136 month Korean KFDA review period for the machine change notification when the scale-up occurs. Korea Ever-Power&#8217;s pharmaceutical application team advises Korean pharmaceutical IBM customers on dual-machine qualification strategy as part of the pre-purchase application consultation for pharmaceutical production lines.<\/p>\n<\/section>\n<p><!-- FAQ --><\/p>\n<section style=\"margin: 56px 0 0; padding: 36px 0 0; border-top: 2px solid #065f46;\">\n<h2 id=\"faq\" style=\"font-size: clamp(19px,2.8vw,25px); font-weight: 800; color: #065f46; margin: 0 0 24px;\">\u0427\u0435\u0441\u0442\u043e \u0437\u0430\u0434\u0430\u0432\u0430\u043d\u0438 \u0432\u044a\u043f\u0440\u043e\u0441\u0438<\/h2>\n<div style=\"display: flex; flex-direction: column; gap: 2px;\">\n<div style=\"border: 1px solid #a7f3d0; border-radius: 8px 8px 0 0; overflow: hidden;\">\n<div style=\"background: #ecfdf5; padding: 14px 20px; border-bottom: 1px solid #a7f3d0;\">\n<p style=\"font-size: 15px; font-weight: bold; color: #065f46; margin: 0;\">Q1 \u2014 What Korean KFDA documentation is required for IBM pharmaceutical container supplier qualification?<\/p>\n<\/div>\n<div style=\"padding: 16px 20px;\">\n<p style=\"font-size: 15px; color: #374151; margin: 0; line-height: 1.7;\">Korean pharmaceutical brands qualifying a new IBM container supplier require a documentation package that Korea Ever-Power provides as standard with every pharmaceutical IBM delivery. The complete package includes: (1) Resin specification \u2014 manufacturer, grade designation, lot number, certificate of analysis including MI, density, melt point, and Korean KFDA positive list reference or KFDA food\/pharmaceutical contact declaration; (2) Container drawing \u2014 all nominal dimensions and tolerances, material identification, volume marking specification, and revision history; (3) Machine and mould identification \u2014 Korea Ever-Power machine serial number, mould serial number, cavity count, and production site address; (4) Cavity-by-cavity dimensional report \u2014 30 measurements per dimension (neck OD, bore diameter, height, volume) across all cavities from 500 consecutive production cycles, verifying that all cavities are within specification simultaneously; (5) Korean Pharmacopoeia plastic container test certificate \u2014 extractables from Korean accredited testing laboratory, confirming compliance with KP limits for HDPE or PP pharmaceutical containers; (6) Closure engagement test report \u2014 CRC function per KS M ISO 8317 (for CRC containers), induction seal bond strength (for induction seal containers), or dropper tip insertion torque (for ophthalmic dropper containers); (7) Chemical compatibility report \u2014 12-week filled stability at 40\u00b0C\/75% RH using the specific pharmaceutical formulation at the proposed container supplier, confirming no extractables above KFDA limits, no dimensional change above specification, and no closure integrity failure. The timeline from IBM machine delivery to full documentation package completion is typically 16\u201320 weeks when all tests proceed in parallel \u2014 the 12-week filled stability test governs the overall timeline.<\/p>\n<\/div>\n<\/div>\n<div style=\"border: 1px solid #a7f3d0; border-top: none; overflow: hidden;\">\n<div style=\"background: #ecfdf5; padding: 14px 20px; border-bottom: 1px solid #a7f3d0;\">\n<p style=\"font-size: 15px; font-weight: bold; color: #065f46; margin: 0;\">Q2 \u2014 How does IBM eliminate particulate contamination risk in Korean pharmaceutical cleanroom production?<\/p>\n<\/div>\n<div style=\"padding: 16px 20px;\">\n<p style=\"font-size: 15px; color: #374151; margin: 0; line-height: 1.7;\">IBM eliminates particulate contamination risk in Korean pharmaceutical cleanroom production through its fundamental process architecture \u2014 not through add-on contamination control measures. Three specific particle generation mechanisms present in EBM are absent from IBM: the flash trim station (where mechanical blades contact the bottle at high speed to remove flash, generating plastic particles that become airborne in the production environment); the flash removal conveyor (where flash pieces are conveyed away from the blow station, and fragmentation of flash pieces in the conveyor generates secondary plastic particles); and the regrind system (where flash is granulated into regrind particles for return to the extruder, and the granulator generates fine plastic dust). In an IBM production cell, none of these mechanisms exist. The IBM machine produces finished containers directly from resin without any intermediate product (flash) that requires mechanical processing. In a Korean pharmaceutical cleanroom IBM cell, the only particle sources are: resin dust from the hopper (controlled by enclosed hopper with filtered vent); mould core rod wear particles (controlled by periodic core rod inspection and replacement schedule); and hydraulic system particles (controlled by hydraulic filter maintenance and pharmaceutical-grade oil specification). All three can be managed to Korean pharmaceutical cleanroom particulate limits with standard cleanroom housekeeping protocols. Korea Ever-Power&#8217;s ZQ series pharmaceutical machine configuration includes hydraulic oil filter grade specification and maintenance interval recommendations that keep hydraulic particle contribution below Korean pharmaceutical cleanroom particulate action limits.<\/p>\n<\/div>\n<\/div>\n<div style=\"border: 1px solid #a7f3d0; border-top: none; overflow: hidden;\">\n<div style=\"background: #ecfdf5; padding: 14px 20px; border-bottom: 1px solid #a7f3d0;\">\n<p style=\"font-size: 15px; font-weight: bold; color: #065f46; margin: 0;\">Q3 \u2014 What is the maximum cavity count available for Korean pharmaceutical CRC container IBM production?<\/p>\n<\/div>\n<div style=\"padding: 16px 20px;\">\n<p style=\"font-size: 15px; color: #374151; margin: 0; line-height: 1.7;\">The maximum cavity count for Korean pharmaceutical CRC container IBM production on Korea Ever-Power&#8217;s ZQ series depends on the container volume. For 100 ml CRC medicine bottles (the most common Korean pharmaceutical CRC format): 14 cavities on the ZQ110 (confirmed production configuration). For 50 ml CRC containers: up to 18 cavities on the ZQ110. For 30 ml CRC vials: up to 22 cavities on the ZQ110 or up to 26 cavities on the ZQ135. The CRC container maximum cavity count is determined by the platen size and 1,100\u20131,350 KN injection clamping force requirements \u2014 at 100 ml CRC, the larger bottle footprint limits the cavity count more than the clamping force per cavity. At 100 ml with 14-cavity ZQ110 production, output is approximately 6,000 CRC medicine bottles per hour at 4-second cycle and 88% efficiency \u2014 approximately 12.6 million CRC medicine bottles per Korean two-shift year. Korean pharmaceutical manufacturers producing single-product annual volumes above 12 million 100 ml CRC bottles should evaluate the ZQ135 at a configuration Korea Ever-Power&#8217;s pharmaceutical application engineers can size for the specific container dimensions and annual production requirement. For smaller CRC formats at higher cavity counts, the ZQ135 at 24-cavity 50 ml CRC produces approximately 10,800 containers per hour \u2014 approximately 22.7 million 50 ml CRC bottles per Korean two-shift year from a single machine.<\/p>\n<\/div>\n<\/div>\n<div style=\"border: 1px solid #a7f3d0; border-top: none; overflow: hidden;\">\n<div style=\"background: #ecfdf5; padding: 14px 20px; border-bottom: 1px solid #a7f3d0;\">\n<p style=\"font-size: 15px; font-weight: bold; color: #065f46; margin: 0;\">Q4 \u2014 How long does Korean pharmaceutical IBM container qualification take from machine order to commercial production approval?<\/p>\n<\/div>\n<div style=\"padding: 16px 20px;\">\n<p style=\"font-size: 15px; color: #374151; margin: 0; line-height: 1.7;\">The Korean pharmaceutical IBM container qualification timeline from machine order to KFDA-approved commercial production has two phases with different timelines. Phase 1 \u2014 Machine and mould delivery and installation: 80\u2013100 days from order confirmation (ZQ80 standard delivery 65\u201380 days machine manufacture + 50\u201365 days mould manufacture in parallel + installation). Phase 2 \u2014 Container qualification and Korean KFDA documentation: 16\u201324 weeks from first production sample. The Phase 2 timeline is dominated by three activities that must run in sequence. First, Korean KP extractables testing: 4\u20136 weeks at a Korean accredited testing laboratory (simultaneous with other testing). Second, filled stability testing: 12 weeks at 40\u00b0C\/75% RH using the actual pharmaceutical formulation \u2014 this is the critical path activity that cannot be accelerated. Third, Korean KFDA container change notification (if required for an existing registered Korean pharmaceutical product): 3\u20136 months for major change review. The total timeline from machine order to commercial production on a new Korean pharmaceutical product (no existing KFDA registration): approximately 7\u20139 months. For an existing Korean registered pharmaceutical product requiring a container change notification: approximately 13\u201315 months (10 months from machine order to complete documentation + 3\u20135 months KFDA review). Korean pharmaceutical brands planning IBM container transitions should build this timeline into their Korean packaging change project plan \u2014 IBM container qualification is not on the machine delivery timeline but on the regulatory review timeline, and the regulatory portion cannot be compressed regardless of how quickly the machine is installed and the documentation is assembled.<\/p>\n<\/div>\n<\/div>\n<div style=\"border: 1px solid #a7f3d0; border-top: none; overflow: hidden;\">\n<div style=\"background: #ecfdf5; padding: 14px 20px; border-bottom: 1px solid #a7f3d0;\">\n<p style=\"font-size: 15px; font-weight: bold; color: #065f46; margin: 0;\">Q5 \u2014 Can IBM containers meet Korean KFDA requirements for sterile pharmaceutical products?<\/p>\n<\/div>\n<div style=\"padding: 16px 20px;\">\n<p style=\"font-size: 15px; color: #374151; margin: 0; line-height: 1.7;\">IBM containers can serve as primary packaging for Korean sterile pharmaceutical products in specific configurations, with the sterility being provided by the filling process rather than the container. For Korean terminally sterilised ophthalmic preparations (eye drops sterilised in the final container by autoclaving or radiation): HDPE IBM containers are compatible with gamma and ethylene oxide sterilisation; PP IBM containers are compatible with steam (autoclave), gamma and EtO sterilisation. The container must be qualified with the specific sterilisation method \u2014 dimensional retention through sterilisation cycles, extractables post-sterilisation within KP limits, and closure integrity post-sterilisation. For Korean aseptically filled sterile pharmaceuticals (filled under sterile conditions without terminal sterilisation): the IBM container is not sterile at the point of fill \u2014 it must be sterilised before aseptic filling by the Korean pharmaceutical manufacturer. Korean aseptic IBM container sterilisation methods include: gamma irradiation at 25\u201340 kGy (HDPE and PP both compatible; verify dimensional retention and extractables post-irradiation with the specific resin grade); ethylene oxide (compatible with both HDPE and PP; EtO residuals must desorb to below Korean MFDS medical device limits before use); hydrogen peroxide vapour sterilisation (compatible with HDPE and PP for surface sterilisation of pre-formed containers; used in Korean pharmaceutical blow-fill-seal adjacent processes). IBM containers are not self-sterilising \u2014 the Korean pharmaceutical manufacturer is responsible for container sterilisation as part of their Korean GMP pharmaceutical production process validation, with the IBM container supplier&#8217;s role being to provide containers that maintain integrity and extractable compliance through the sterilisation method.<\/p>\n<\/div>\n<\/div>\n<div style=\"border: 1px solid #a7f3d0; border-radius: 0 0 8px 8px; overflow: hidden;\">\n<div style=\"background: #ecfdf5; padding: 14px 20px; border-bottom: 1px solid #a7f3d0;\">\n<p style=\"font-size: 15px; font-weight: bold; color: #065f46; margin: 0;\">Q6 \u2014 What is the difference between primary and secondary pharmaceutical packaging in Korean IBM production context?<\/p>\n<\/div>\n<div style=\"padding: 16px 20px;\">\n<p style=\"font-size: 15px; color: #374151; margin: 0; line-height: 1.7;\">In Korean pharmaceutical packaging regulation, primary packaging is the packaging that is in direct contact with the pharmaceutical product \u2014 the HDPE or PP IBM bottle that contains the eye drops, oral liquid, or medicine. Secondary packaging is the outer packaging that surrounds the primary container \u2014 the cardboard carton, the blister tray, or the shipper box. IBM containers are pharmaceutical primary packaging, subject to the full Korean KFDA pharmaceutical container qualification requirements described in this guide. Secondary packaging is not subject to Korean KFDA pharmaceutical plastic container standards \u2014 only general Korean packaging material standards apply. The primary\/secondary distinction matters for Korean IBM packaging producers in two practical ways. First, regulatory pathway: primary container changes (material, supplier, dimensions) require Korean KFDA notification per Korean Pharmaceutical Affairs Act Article 32; secondary packaging changes are typically handled through the Korean pharmaceutical manufacturer&#8217;s internal change control process without Korean KFDA notification. Second, cleanroom requirement: Korean pharmaceutical primary container production (IBM containers) is subject to Korean GMP cleanroom environmental requirements; secondary packaging production is not. Korean IBM producers supplying pharmaceutical primary containers must demonstrate Korean GMP-compliant production conditions (environmental monitoring, personnel hygiene, validated cleaning procedures) that secondary packaging producers \u2014 such as Korean carton printers \u2014 are not required to demonstrate. This distinction explains why Korean pharmaceutical primary container IBM production is typically conducted in dedicated cleanroom production areas separated from the Korean IBM producer&#8217;s general commercial packaging production operations.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n<p><!-- CTA --><\/p>\n<div style=\"background: linear-gradient(135deg,#021a0c 0%,#065f46 100%); border-radius: 10px; padding: clamp(30px,5vw,50px) clamp(20px,4vw,40px); text-align: center; margin: 56px 0 48px;\">\n<p style=\"font-size: 10px; font-weight: bold; letter-spacing: 2px; text-transform: uppercase; color: #6ee7b7; margin: 0 0 12px;\">Pharmaceutical IBM Enquiry<\/p>\n<h2 style=\"font-size: clamp(18px,3vw,26px); font-weight: 800; color: #fff; margin: 0 0 14px;\">Specifying IBM Containers for Korean Pharmaceutical Production?<\/h2>\n<p style=\"font-size: 15px; color: #a7f3d0; max-width: 480px; margin: 0 auto 26px; line-height: 1.65;\">Korea Ever-Power provides pharmaceutical IBM container dimensional qualification, Korean KFDA documentation packages, cleanroom machine configuration and ZQ series machine selection for Korean pharmaceutical primary packaging at all production scales.<\/p>\n<p><a style=\"display: inline-block; background: #f97316; color: #fff; padding: 14px 36px; border-radius: 6px; text-decoration: none; font-weight: bold; font-size: 15px;\" href=\"https:\/\/isbm-blow-molding.com\/bg\/contact-us\/\">Request Pharmaceutical IBM Consultation<\/a><\/p>\n<\/div>\n<p><!-- RELATED RESOURCES --><\/p>\n<section style=\"margin-bottom: 56px;\">\n<p style=\"font-size: 10.5px; font-weight: bold; letter-spacing: 2px; text-transform: uppercase; color: #065f46; margin-bottom: 16px;\">\u0421\u0432\u044a\u0440\u0437\u0430\u043d\u0438 \u0440\u0435\u0441\u0443\u0440\u0441\u0438<\/p>\n<div style=\"display: flex; flex-wrap: wrap; gap: 16px;\">\n<div style=\"background: #fff; border: 1.5px solid #a7f3d0; border-top: 4px solid #065f46; border-radius: 8px; padding: 18px 20px;\"><span style=\"display: block; font-size: 9px; font-weight: bold; color: #f97316; letter-spacing: 1.5px; text-transform: uppercase; margin-bottom: 8px;\">Large Pharma IBM<\/span><br \/>\n<span style=\"display: block; font-size: 15px; font-weight: bold; color: #1e3a8a; margin-bottom: 8px; line-height: 1.3;\">\u041c\u0430\u0448\u0438\u043d\u0430 \u0437\u0430 \u0448\u043f\u0440\u0438\u0446\u0432\u0430\u043d\u0435 \u0441 \u0440\u0430\u0437\u0434\u0443\u0432\u043d\u0430 \u043b\u0435\u0435\u043d\u0435 \u043f\u043e\u0434 \u043d\u0430\u043b\u044f\u0433\u0430\u043d\u0435 EP-ZQ110<\/span><br \/>\n<span style=\"display: block; font-size: 13px; color: #6b7280; line-height: 1.55;\">1,100 KN \u00b7 24 cavities at 10 ml pharmaceutical \u00b7 4+N barrel zones \u00b7 22+22 KW dual hydraulic \u00b7 ~50M\u201365M ophthalmic containers per Korean two-shift year.<\/span><\/div>\n<p>&nbsp;<\/p>\n<div style=\"background: #fff; border: 1.5px solid #a7f3d0; border-top: 4px solid #065f46; border-radius: 8px; padding: 18px 20px;\"><span style=\"display: block; font-size: 9px; font-weight: bold; color: #f97316; letter-spacing: 1.5px; text-transform: uppercase; margin-bottom: 8px;\">Mega-Scale Pharma IBM<\/span><br \/>\n<span style=\"display: block; font-size: 15px; font-weight: bold; color: #1e3a8a; margin-bottom: 8px; line-height: 1.3;\">\u041c\u0430\u0448\u0438\u043d\u0430 \u0437\u0430 \u0448\u043f\u0440\u0438\u0446\u0432\u0430\u043d\u0435 \u0441 \u0440\u0430\u0437\u0434\u0443\u0432\u043d\u0430 \u043b\u0435\u0435\u043d\u0435 \u043f\u043e\u0434 \u043d\u0430\u043b\u044f\u0433\u0430\u043d\u0435 EP-ZQ135<\/span><br \/>\n<span style=\"display: block; font-size: 13px; color: #6b7280; line-height: 1.55;\">1,350 KN \u00b7 30 cavities at 10 ml \u00b7 6+N barrel zones \u00b7 37+37 KW \u00b7 Korean national pharmaceutical hospital supply \u2014 83M ophthalmic containers per year per machine.<\/span><\/div>\n<p>&nbsp;<\/p>\n<div style=\"background: #fff; border: 1.5px solid #a7f3d0; border-top: 4px solid #065f46; border-radius: 8px; padding: 18px 20px;\"><span style=\"display: block; font-size: 9px; font-weight: bold; color: #f97316; letter-spacing: 1.5px; text-transform: uppercase; margin-bottom: 8px;\">Process Guide<\/span><br \/>\n<span style=\"display: block; font-size: 15px; font-weight: bold; color: #1e3a8a; margin-bottom: 8px; line-height: 1.3;\">IBM vs ISBM: Choosing the Right Process<\/span><br \/>\n<span style=\"display: block; font-size: 13px; color: #6b7280; line-height: 1.55;\">Why HDPE and PP pharmaceutical containers use IBM while PET cosmetic and beverage containers use ISBM \u2014 material, neck precision and output rate comparison for Korean pharmaceutical packaging decisions.<\/span><\/div>\n<p>&nbsp;<\/p>\n<\/div>\n<\/section>\n<p>&nbsp;<\/p>\n<footer style=\"text-align: center; padding: 32px 0 24px; border-top: 1px solid #e5e7eb;\">\n<p style=\"font-size: 12px; color: #9ca3af; margin: 0;\">\u0420\u0435\u0434\u0430\u043a\u0442\u043e\u0440: Cxm<\/p>\n<\/footer>\n<p>&nbsp;<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Pharmaceutical IBM \u00b7 Korean KFDA GMP \u00b7 Korea Ever-Power Injection Blow Molding for Pharmaceutical Bottles Injection blow molding is the process standard for Korean pharmaceutical primary packaging in HDPE and PP. It is the only blow molding process that consistently meets Korean KFDA GMP dimensional requirements for CRC containers without secondary neck processing, eliminates particulate [&hellip;]<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[26],"tags":[],"class_list":["post-1045","post","type-post","status-publish","format-standard","hentry","category-application-of-isbm"],"_links":{"self":[{"href":"https:\/\/isbm-blow-molding.com\/bg\/wp-json\/wp\/v2\/posts\/1045","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/isbm-blow-molding.com\/bg\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/isbm-blow-molding.com\/bg\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/isbm-blow-molding.com\/bg\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/isbm-blow-molding.com\/bg\/wp-json\/wp\/v2\/comments?post=1045"}],"version-history":[{"count":4,"href":"https:\/\/isbm-blow-molding.com\/bg\/wp-json\/wp\/v2\/posts\/1045\/revisions"}],"predecessor-version":[{"id":1050,"href":"https:\/\/isbm-blow-molding.com\/bg\/wp-json\/wp\/v2\/posts\/1045\/revisions\/1050"}],"wp:attachment":[{"href":"https:\/\/isbm-blow-molding.com\/bg\/wp-json\/wp\/v2\/media?parent=1045"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/isbm-blow-molding.com\/bg\/wp-json\/wp\/v2\/categories?post=1045"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/isbm-blow-molding.com\/bg\/wp-json\/wp\/v2\/tags?post=1045"}],"curies":[{"name":"\u0440\u0430\u0431\u043e\u0442\u043d\u0430 \u0441\u0440\u0435\u0449\u0430","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}